Generic Sterile Injectable Market Size to Hit USD 116.49 Bn by 2034

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Generic Sterile Injectable Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Generic Sterile Injectable Market

5.1. Covid-19: generic sterile injectable Industry Impact
5.2. generic sterile injectable Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and generic sterile injectable Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for generic sterile Injectable Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Generic Sterile Injectable Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. The convenience of sterile injectable in medical treatment boosts the market
6.1.1.2. Development in biotechnology aids rapid investment in injectable
6.1.1.3. Increasing prevalence of chronic illnesses across the globe
6.1.2. Market Restraints
6.1.2.1. High entry barriers due to demanding compliance requirements
6.1.3. Market Opportunities
6.1.3.1. Expiry of patents

Chapter 7. Global Generic Sterile Injectable Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. generic sterile Injectable Market Revenue by Market Players
7.1.1.2. generic sterile Injectable Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Generic Sterile Injectable Market, By Product Type

8.1. generic sterile Injectable Market, by Product Type
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue Forecast
8.1.2. Cytokines
8.1.2.1. Market Revenue Forecast
8.1.3. Insulin
8.1.3.1. Market Revenue Forecast
8.1.4. Peptide Hormones
8.1.4.1. Market Revenue Forecast
8.1.5. Vaccines
8.1.5.1. Market Revenue Forecast
8.1.6. Immunoglobulin
8.1.6.1. Market Revenue Forecast
8.1.7. Blood Factors
8.1.7.1. Market Revenue Forecast
8.1.8. Antibiotics
8.1.8.1. Market Revenue Forecast
8.1.9. Others
8.1.9.1. Market Revenue Forecast

Chapter 9. Global Generic Sterile Injectable Market, By Therapeutic Application

9.1. generic sterile injectable Market, by Therapeutic Application
9.1.1. Cancer
9.1.1.1. Market Revenue Forecast
9.1.2. Diabetes
9.1.2.1. Market Revenue Forecast
9.1.3. Cardiovascular Disease
9.1.3.1. Market Revenue Forecast
9.1.4. Central Nervous System
9.1.4.1. Market Revenue Forecast
9.1.5. Musculoskeletal System
9.1.5.1. Market Revenue Forecast
9.1.6. Others
9.1.6.1. Market Revenue Forecast

Chapter 10. Global Generic Sterile Injectable Market, By Distribution Channel

10.1. generic sterile injectable Market, by Distribution Channel
10.1.1. Hospitals
10.1.1.1. Market Revenue Forecast
10.1.2. Drug Stores
10.1.2.1. Market Revenue Forecast
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue Forecast
10.1.4. Others
10.1.4.1. Market Revenue Forecast

Chapter 11. Global Generic Sterile Injectable Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Product Type
11.1.2. Market Revenue Forecast by Therapeutic Application
11.1.3. Market Revenue Forecast by Distribution Channel
11.1.4. U.S
11.1.4.1. Market Revenue Forecast
11.1.5. Canada
11.1.5.1. Market Revenue Forecast
11.2. Europe
11.2.1. Market Revenue Forecast by Product Type
11.2.2. Market Revenue Forecast by Therapeutic Application
11.2.3. Market Revenue Forecast by Distribution Channel
11.2.4. UK
11.2.4.1. Market Revenue Forecast
11.2.5. Germany
11.2.5.1. Market Revenue Forecast
11.2.6. France
11.2.6.1. Market Revenue Forecast
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product Type
11.3.2. Market Revenue Forecast by Therapeutic Application
11.3.3. Market Revenue Forecast by Distribution Channel
11.3.4. China
11.3.4.1. Market Revenue Forecast
11.3.5. India
11.3.5.1. Market Revenue Forecast
11.3.6. Japan
11.3.6.1. Market Revenue Forecast
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast
11.4. LATAM
11.4.1. Market Revenue Forecast by Product Type
11.4.2. Market Revenue Forecast by Therapeutic Application
11.4.3. Market Revenue Forecast by Distribution Channel
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product Type
11.5.2. Market Revenue Forecast by Therapeutic Application
11.5.3. Market Revenue Forecast by Distribution Channel
11.5.4. GCC
11.5.4.1. Market Revenue Forecast
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast

Chapter 12. Company Profiles

12.1. Fresenius Kabi
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin (2017-2020)
12.1.4. Recent Developments and Strategies
12.2. Baxter
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin (2017-2020)
12.2.4. Recent Developments and Strategies
12.3. Civica
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin (2017-2020)
12.3.4. Recent Developments and Strategies
12.4. Pfizer
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin (2017-2020)
12.4.4. Recent Developments and Strategies
12.5. Mylan
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin (2017-2020)
12.5.4. Recent Developments and Strategies
12.6. Hikma
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin (2017-2020)
12.6.4. Recent Developments and Strategies
12.7. Sandoz
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin (2017-2020)
12.7.4. Recent Developments and Strategies
12.8. Teva
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin (2017-2020)
12.8.4. Recent Developments and Strategies
12.9. Nichi-Iko
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin (2017-2020)
12.9.4. Recent Developments and Strategies
12.10. 3M
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin (2017-2020)
12.10.4. Recent Developments and Strategies
12.11. Merck & Co., Inc.
12.11.1. Company Overview, Business Information, Regional Presence
12.11.2. Product Portfolio Analysis
12.11.2.1. Product Details, Specification, Application
12.11.3. Revenue, Price, and Gross Margin (2017-2020)
12.11.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

According to Precedence Research, the generic sterile injectable market was valued at USD 42.39 billion in 2023 is anticipated to reach over USD 108.54 billion by 2033.

The demand for sterile injectable in the coming years is expected to drive a growing prevalence of chronic diseases, particularly cancer, across the globe. Moreover, the growth of the global industry is also being fuelled by a rising number of drug manufacturers focused on the development of cancer drugs. In addition, rapid FDA sterile injectable drug approvals coupled with shortened approval times for new drug manufacture in cancer treatment are growing the availability of dive drugs and ultimately powering demand in the generic sterile injectable market.

The global generic sterile injectable market is growing at a noteworthy CAGR of 9.85% during the forecast period 2024 to 2033.

In year 2023, North America conquered the worldwide market with a market share of greater than 39.05%.

The key companies functioning in the worldwide generic sterile injectable are Baxter, Hikma, Mylan, Fresenius Kabi, Sandoz, Pfizer, Civica, Merck & Co., Inc. Teva, 3M, Nichi-Iko among others.

The generic sterile injectable refers to the biologics used for the treatment of a variety of medications which includes the same active ingredients found in the marketed versions. Its inactive contents can, however, vary from one another. The generic sterile injectable development process is governed by the U.S. The FDA and its marketed equivalents are similar. U.S. according to National Center for Health Information, it is considered a chronic condition when the disease lasts more than three months within the patient. Chronic diseases are one of the key causes of death, as vaccines and other drugs do not cure them quickly.